Hyper (A065650) Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A065650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hyper Corporation Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,080.00 |
| 52 Week High | ₩11,592.00 |
| 52 Week Low | ₩1,424.00 |
| Beta | 1.63 |
| 1 Month Change | -19.54% |
| 3 Month Change | -52.29% |
| 1 Year Change | -79.17% |
| 3 Year Change | -79.77% |
| 5 Year Change | -93.57% |
| Change since IPO | -91.33% |
Recent News & Updates
Is Hyper (KOSDAQ:065650) A Risky Investment?
Dec 01
We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of Debt
Jun 26Shareholder Returns
| A065650 | KR Electronic | KR Market | |
|---|---|---|---|
| 7D | 0.2% | 3.9% | 3.3% |
| 1Y | -79.2% | 66.9% | 67.7% |
Return vs Industry: A065650 underperformed the KR Electronic industry which returned 75.7% over the past year.
Return vs Market: A065650 underperformed the KR Market which returned 73% over the past year.
Price Volatility
| A065650 volatility | |
|---|---|
| A065650 Average Weekly Movement | 15.5% |
| Electronic Industry Average Movement | 6.5% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A065650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A065650's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 46 | Hyun-Sang Muk | www.hyper-corp.com |
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents.
Hyper Corporation Inc. Fundamentals Summary
| A065650 fundamental statistics | |
|---|---|
| Market cap | ₩27.68b |
| Earnings (TTM) | -₩51.94b |
| Revenue (TTM) | ₩71.49b |
Is A065650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A065650 income statement (TTM) | |
|---|---|
| Revenue | ₩71.49b |
| Cost of Revenue | ₩61.79b |
| Gross Profit | ₩9.69b |
| Other Expenses | ₩61.63b |
| Earnings | -₩51.94b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.90k |
| Gross Margin | 13.56% |
| Net Profit Margin | -72.65% |
| Debt/Equity Ratio | 243.2% |
How did A065650 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/09 01:20 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyper Corporation Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| NaYeon Kim | Mirae Asset Securities Co., Ltd. |